References
- van den Beuken-van EverdingenMHde RijkeJMKesselsAGSchoutenHCvan KleefMPatijnJPrevalence of pain in patients with cancer: a systematic review of the past 40 yearsAnn Oncol20071891437144917355955
- MenahemSShvartzmanPHigh-dose fentanyl patch for cancer painJ Am Board Fam Pract200417538839015355954
- RadbruchLSabatowskiRPetzkeFBrunsch-RadbruchAGrondSLehmannKATransdermal fentanyl for the management of cancer pain: a survey of 1005 patientsPalliat Med200115430932112054148
- LabrooRBPaineMFThummelKEKharaschEDFentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactionsDrug Metab Dispos1997259107210809311623
- GrondSRadbruchLLehmannKAClinical pharmacokinetics of trans-dermal opioids: focus on transdermal fentanylClin Pharmacokinet2000381598910668859
- FearonKStrasserFAnkerSDDefinition and classification of cancer cachexia: an international consensusLancet Oncol201112548949521296615
- RadbruchLElsnerFTrottenbergPStrasserFFearonKClinical Practice Guidelines on Cancer Cachexia in Advanced Cancer Patients with a Focus on refractory CachexiaAachenDepartment of Palliative Medicine, European Palliative Care Research Collaborative2010 Available from: http://www.epcrc.org/guidelines.php?p=cachexiaAccessed February 15, 2015
- DouglasEMcMillanDCTowards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic ScoreCancer Treat Rev201440668569124321611
- SlavieroKAClarkeSJRivoryLPInflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapyLancet Oncol20034422423212681266
- NaitoTTashiroMIshidaTOhnishiKKawakamiJCancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patientsJ Clin Pharmacol201353881281823733622
- Food and Drug Administration [homepage on the Internet]Silver SpringGuidance for industry analytical procedures and methods validation for drugs and biologics [updated 2014 Feb; cited 2014 Sep 10] Available from: http://www.fda.gov/downloads/Drugs/GuidanceCom-plianceRegulatoryInformation/Guidances/UCM386366.pdfAccessed September 10, 2014
- National Institutes of Health [homepage on the Internet]BethesdaCommon Terminology Criteria for Adverse Events (CTCAE) Version 4.0320092010 [updated 2010 Jun 14; cited 2014 Sep 10] Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdfAccessed September 10, 2014
- HeiskanenTMätzkeSHaakanaSGergovMVuoriEKalsoETransdermal fentanyl in cachectic cancer patientsPain20091441–221822219442446
- KoehntopDERodmanJHFentanyl pharmacokinetics in patients undergoing renal transplantationPharmacotherapy19971747467529250552
- PhamPCTToscanoEPhamPMTPhamPATPhamSVPhamPTTPain management in patients with chronic kidney diseaseNDT Plus20092211111825949305
- MantovaniGMacciòAMadedduCQuantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance statusInt J Cancer2002981849111857390
- RivoryLPSlavieroKAClarkeSJHepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase responseBr J Cancer200287327728012177794
- JoverRBortRGómez-LechónMJCastellJVDown-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involvedFASEB J200216131799180112354697
- Fentos® tape [Drug interview form]Saga, JapanHisamitsu Pharmaceutical Co, IncTokyoKyowa Hakko Kirin Co, Ltd2011